1274
Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.
 a patient with APL: Subject; symptom complex referred to as "retinoic acid syndrome.": Effect; a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis: Treatment; ATRA: Treatment.Drug; a few weeks: Treatment.Time_elapsed; APL: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with APL: Subject; symptom complex referred to as "retinoic acid syndrome.": Effect; a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis: Treatment; ATRA: Treatment.Drug; a few weeks: Treatment.Time_elapsed; APL: Treatment.Disorder